Table 5.
Adverse Events: Number of Patients With Adverse Events/Total Number of Patients
| IVM annual | IVM semiannual | IVM + ALB annual | IVM + ALB semiannual | |
|---|---|---|---|---|
| 0 months | 43/68 (63.2%) | 48/67 (71.6%) | 50/70 (71.4%) | 45/66 (68.2%) |
| 6 months | 11/62 (17.7%) | 16/66 (24.2%) | 5/66 (7.6%) | 16/63 (25.4%) |
| 12 months | 9/66 (13.6%) | 6/62 (9.7%) | 13/67 (19.4%) | 11/62 (17.7%) |
| 18 months | 6/62 (9.7%) | 13/64 (20.3%) | 4/64 (6.3%) | 7/60 (11.7%) |
| 24 months | 8/63 (12.7%) | 6/65 (9.2%) | 12/66 (18.2%) | 7/60 (11.7%) |
Abbreviations: ALB, albendazole; IVM, ivermectin.